论文部分内容阅读
目的:观察重组白细胞介素-2(IL-2)在顽固性气胸中的治疗效果。方法:将64例顽固性气胸患者随机分为IL-2组(治疗组)和凝血酶组(对照组)。在胸腔闭式引流基础上,分别往胸腔内注入IL-2 150万IU或凝血酶1 000 IU。结果:两组有效率及不良反应差别无统计学意义(P>0.05)。结论:胸腔内注射IL-2治疗顽固性气胸是一种安全,有效的方法。
Objective: To observe the therapeutic effect of recombinant interleukin-2 (IL-2) in refractory pneumothorax. Methods: Sixty-four patients with refractory pneumothorax were randomly divided into IL-2 group (treatment group) and thrombin group (control group). On the basis of closed thoracic drainage, respectively, to the intrathoracic injection of IL-2 1.5 million IU or thrombin 1000 IU. Results: There was no significant difference between the two groups in the efficacy and adverse reactions (P> 0.05). Conclusion: Intrathoracic injection of IL-2 in refractory pneumothorax is a safe and effective method.